Business
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The Company’s poster presentations will explore the age of onset of social anxiety disorde
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/6ee8bc976214ceec01e35edff64ad0bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G7p.pfGpHCzfkrvpn35bdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6ee8bc976214ceec01e35edff64ad0bc","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/k4iFiemCY5BDph6OkP_zCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6ee8bc976214ceec01e35edff64ad0bc","width":1200,"height":325}},"lazy":false},{"type":"text","content":"Posters Highlight New Insights into Social Anxiety Disorder and the Novel Mechanism of Action of Itruvone to Treat Major Depressive Disorder","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 23, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The Company’s poster presentations will explore the age of onset of social anxiety disorder (SAD) from participants in fasedienol clinical trials, and the impact of itruvone – the company’s investigational pherine for the treatment of major depressive disorder – on the electrogram of nasal chemosensory receptors (EGNR) and the olfactory bulb electrogram (EBG), both biomarkers of itruvone’s effect on nasal chemosensory neurons and olfactory bulb physiologic activation.","length":899,"tagName":"p"},{"type":"text","content":"Poster Presentations:","length":21,"tagName":"p"},{"type":"text","content":"Date: Wednesday, May 28, 2025, 11:15 a.m. – 1:00 p.m. Eastern TimeTitle: Age of Onset of Social Anxiety Disorder (SAD) in Trials of Fasedienol (PH94B) Nasal SprayAuthors: Ester Salmán, MPH; Ross A. Baker, PhD; Stephen D. Coffey, BA; Rita Hanover, PhD; Michael R. Liebowitz, MD; and Louis Monti, MD, PhDPoster Number: W5","length":322,"tagName":"p"},{"type":"text","content":"Date: Thurs...